Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Increase in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 17,700 shares, an increase of 785.0% from the February 13th total of 2,000 shares. Based on an average daily trading volume, of 301,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Appili Therapeutics Stock Down 9.2 %

APLIF stock opened at $0.02 on Friday. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.05. The business has a 50 day moving average of $0.02 and a 200-day moving average of $0.02. The firm has a market cap of $2.75 million, a PE ratio of -1.14 and a beta of -0.55.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.